March 5, 2021

Syros Initiates a Phase III Clinical Trial of Tamibarotene in Combination with Azacitidine for Higher-Risk MDS

March 4, 2021 (US time) – Syros Pharmaceuticals Inc. (Headquarters: Cambridge, Massachusetts, U.S.A.; President and CEO: Nancy Simonian; hereinafter "Syros") today announced that the company has initiated a phase III clinical trial in the U.S. since February 2021 for a retinoic acid receptor agonist (tamibarotene/TM-411/SY-1425, hereinafter "tamibarotene"), which has been licensed by TMRC Co., Ltd. (TMRC), the consolidated subsidiary of RaQualia Pharma Inc. (RaQualia). Syros is currently screening subjects for the clinical study. Once the subjects are enrolled, they will be administered sequentially.

This phase III clinical trial is a comparative study in patients with RARA-positive untreated HR-MDS (higher-risk myelodysplastic syndrome) to compare the response rate (CR rate) of tamibarotene in combination with azacitidine (Bristol Myers Squibb) with that of placebo in combination with azacitidine.

In September 2015, TMRC signed a license agreement to grant Syros the right to develop and commercialize tamibarotene as a cancer drug for North American and European territories. Syros is evaluating the usefulness of tamibarotene for cancer treatment using the biomarker developed by the company. With the progress of the clinical development by Syros, TMRC is entitled to receive a lump sum payment as well as milestones and post-launch royalties depending on the development stage.

End

Reference:
For Syros' official announcement, please view the website at:
https://ir.syros.com/press-releases/detail/215/syros-reports-fourth-quarter-and-full-year-2020-financial